Clinical Trial Update: Avelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating avelumab with cetuximab and irinotecan for treatment-refractory metastatic colorectal cancer that is microsatellite stable.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Neoplasms Malignant

Drugs mentioned

• Avelumab (avelumab)
• Cetuximab (cetuximab)
• Irinotecan (Irinotecan)

Snippet

Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Conditions: Colorectal Neoplasms, Malignant | Phase 2 | Status: UNKNOWN